Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Cefadroxil · 2 trials · 1 indication
Bioequivalence based on Cmax.
Bioequivalence based on AUC0-t.
Bioequivalence based on AUC0-inf.
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Cefadroxil 500 mg Capsules | DRUG | 1 x 500 mg |
| DURICEF® capsules 500 mg | DRUG | 1 x 500 mg |
Inclusion Criteria: * Non-smoking male or female with a minimum age of 18 years (i.e. non-smoker or non-tobacco user for at least 90 days prior to pre-study medical screening. * Body mass index (BMI= weight/height2 greater than or equal to 19kg/m2 and less than or equal to 30kg/m2. * Availability o...
Cefadroxil is an antibiotic being studied in healthy volunteers. It is currently in Phase 1 clinical development, with two completed trials evaluating the drug in healthy adult subjects. The drug is being developed by Teva Pharmaceutical Industries Limited.
Cefadroxil is being developed by Teva Pharmaceutical Industries Limited, a company traded on the New York Stock Exchange under the ticker TEVA. The drug is currently in Phase 1 clinical development.
Cefadroxil is in Phase 1 clinical development. Two Phase 1 trials have been completed, both involving healthy volunteers. The drug is investigational and has not been approved for any indication.
Cefadroxil has two completed Phase 1 trials: NCT00834275, a study of Cefadroxil 500 mg capsules under fasting conditions, and NCT00835081, a study in normal healthy non-smoking male and female subjects. Each trial enrolled 26 participants.
Cefadroxil 500 mg capsules is the formulation used in the clinical trials of Cefadroxil. The trials NCT00834275 and NCT00835081 both evaluated this specific dosage form in healthy volunteers.